DIA Europe 2023 Highlights
Three-day event concludes with over 1,700 attendees and announcement of its DIA Europe Inspire Awards 2023 winners.
The 35th edition of DIA Europe concluded last month in Basel, Switzerland, with the three-day congress attracting over 1,700 attendees from across the globe, according to the organization.
DIA Europe 2023 featured leading European regulators, industry, HTA bodies, and patient representatives to discuss pressing healthcare challenges, explore innovations, and harmonize key policy decisions with patients' needs.Over 300 speakers, including approximately 30 EMA and European Commission speakers, participated in more than 100 sessions and hands-on workshops on a wide range of topics, including AI and data science, clinical trials, pharmacovigilance and safety, EU health policy, regulatory operations, and medical devices.
In addition, more than 80 exhibitors showcased their latest products and services across all three days.
There was also ample opportunity to recognize the outstanding contributions of several individuals in the life sciences industry to the mission of DIA. The winners of the DIA Europe Inspire Awards 2023 are:
- Excellence in Service Award: Peter Arlett, Head of Pharmacovigilance and Epidemiology Department, European Medicines Agency
- Excellence in Service Award: Isabelle Stoeckert, VP, Head Regulatory Affairs EMEA, AG Pharma Bayer
- Excellence in Service Award - Middle East: Bandar Alhammad, Chief Pharmacist, Executive Directorate of Regulatory Affairs, Saudi Food and Drug Authority
- Outstanding Contribution to Health Award: Anthony Humphreys, Head of Sector Regulatory Affairs Committee Support and Community Procedures, European Medicines Agency
- Outstanding Contribution to Health Award: Vaccines Europe
The
Reference: DIA EUROPE 2023 – PRESS ANNOUNCEMENT, Basel, Switzerland.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025